8-K: INmune Bio Presents Data on Alzheimer's Trial Participants at International Conference

INmune Bio presented baseline demographics and disease profiles of participants in its MINDFuL Phase II study for early Alzheimer's disease at a major European conference.

Summary

• INmune Bio Inc. announced it will present a poster at the International Conference on Alzheimer's and Parkinson's Diseases in Vienna, Austria, from April 1-5, 2025.
• The poster details the demographics and biomarker status of patients enrolled in the MINDFuL Phase II trial, which is a blinded, randomized, placebo-controlled study.
• The trial includes 208 patients diagnosed with either Mild Cognitive Impairment (MCI, 44%) or mild Alzheimer's disease (mAD, 56%).
• The average age of participants is 72 years.
• All patients met criteria for at least one biomarker of inflammation, such as hsCRP > 1.5 mg/L, ESR > 10 mm/hr, HbA1c > 6.0 %, or at least one APOE 4 allele.
• Patients were randomized 2:1 to receive either XPro 1.0 mg/kg or placebo weekly for 23 weeks.
• The primary endpoint is the change from baseline in cognitive scores measured by the Early and Mild Alzheimer's Cognitive Composite (EMACC).
• Topline results of the MINDFuL trial are expected in June 2025.

Sentiment

Score: 7

Explanation: The announcement is positive as it highlights the progress of the MINDFuL trial and the presentation of data at a major conference. However, the forward-looking statements include standard disclaimers about risks and uncertainties, which temper the overall sentiment.

Positives

• The MINDFuL trial has enrolled a well-characterized cohort of patients with early Alzheimer's and biomarker-confirmed inflammation.
• Baseline demographics and disease characteristics of the trial participants are similar to those in successful Phase III trials in early Alzheimer's.
• The EMACC endpoint shows good construct validity, correlating with MMSE and CDR-SB scores.
• The company is using a precision medicine approach for diseases driven by chronic inflammation and cancer.

Negatives

• The screen failure rate in the MINDfuL trial was 72%, with disease severity as measured by screening MMSE as the most common reasons for exclusion.

Risks

• Clinical trials are in early stages and there is no assurance that any specific outcome will be achieved.
• The company's ability to produce more drug for clinical trials is a risk.
• The availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization is a risk.
• CORDStrom, XPro1595 (XPro), and INKmune are still in clinical trials or preparing to start clinical trials and have not been approved by the US Food and Drug Administration (FDA) or any regulatory body and there cannot be any assurance that they will be approved by the FDA or any regulatory body or that any specific results will be achieved.

Future Outlook

Topline results of the MINDFuL trial are expected to be reported in June 2025.

Management Comments

• Preliminary analyses of blinded data at baseline show enrollment of a well-characterized cohort of patients with Early AD and biomarker confirmed inflammation indicative of immune system dysfunction, said CJ Barnum, VP of CNS Drug Development at INmune Bio.

Industry Context

This announcement positions INmune Bio within the competitive landscape of companies developing treatments for Alzheimer's disease, particularly those targeting inflammation as a key driver of the disease. The company is presenting at a major European conference, increasing its visibility among researchers and potential partners.

Comparison to Industry Standards

• The study design and patient characteristics are similar to those in successful Phase III trials in Early AD, suggesting that the company is following industry best practices.
• The use of EMACC as a primary endpoint is consistent with the trend towards more sensitive cognitive measures in early AD clinical trials.
• The screen failure rate in the MINDfuL trial was 72%, with disease severity as measured by screening MMSE as the most common reasons for exclusion.

Stakeholder Impact

• Positive for shareholders as it demonstrates progress in the company's clinical development program.
• Potentially positive for patients with Alzheimer's disease and their families, as it represents a step towards developing new treatments.
• Positive for the company's reputation and visibility within the scientific community.

Next Steps

• The company will present the poster at the AD/PD conference from April 1-5, 2025.
• Topline results of the MINDFuL trial will be reported in June 2025.

Key Dates

Keywords

Alzheimer's disease, INmune Bio, MINDFuL trial, XPro, inflammation, clinical trial, biomarkers, neurodegenerative diseases